Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus
NCT00134940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2011-06-16
Summary
The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants.
Primary outcome measures: incidence of acute rejection episodes Secondary outcomes: safety
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-01-31
- Primary Completion
- 2006-11-30
- Completion
- 2006-11-30
Countries
- Austria
- Germany
Study Locations
More Related Trials
-
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
NCT00097968 ·Status: COMPLETED ·Phase: PHASE3
-
SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
NCT01266148 ·Status: COMPLETED ·Phase: PHASE4
-
Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
NCT00170859 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients
NCT00098007 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients
NCT00154297 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
NCT00862979 ·Status: COMPLETED ·Phase: PHASE4
-
This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus
NCT00531063 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients
NCT00170833 ·Status: COMPLETED ·Phase: PHASE3
-
Everolimus Monotherapy as Immunosuppression After Liver Transplant
NCT04063865 ·Status: TERMINATED ·Phase: PHASE3
-
Everolimus in de Novo Kidney Transplant Recipients
NCT01410448 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients
NCT01404325 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
NCT01114529 ·Status: COMPLETED ·Phase: PHASE3
-
SCHEDULE Follow Up Visit 5-7 yr
NCT02864706 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
NCT00716573 ·Status: COMPLETED ·Phase: PHASE4
-
Safe Renal Function In Long Term Heart Transplanted Patients
NCT00505102 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program
NCT00956293 ·Status: TERMINATED ·Phase: PHASE4
-
Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients
NCT00464399 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients
NCT01551212 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
NCT02134899 ·Status: COMPLETED ·Phase: PHASE3
-
Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation
NCT00402532 ·Status: COMPLETED ·Phase: PHASE3
-
EVR and EPO for Liver Transplant Tolerance
NCT06832189 ·Status: RECRUITING ·Phase: PHASE1
-
A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
NCT02040584 ·Status: COMPLETED ·Phase: PHASE3
-
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
NCT00369161 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
NCT03596970 ·Status: WITHDRAWN ·Phase: PHASE3
-
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
NCT06280950 ·Status: RECRUITING ·Phase: PHASE2